Unicycive Therapeutics
UNCY · Nasdaq · United States
Share price · UNCY
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when UNCY's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 26 Oct 2026-8.0%
- 2 Oct 2026-7.3%
- 1 Jul 2026+12.6%
- 30 Jun 2026-39.1%
- 26 Jun 2026-13.2%
Nothing announced by UNCY that day or the session before.
- 22 Jun 2026+14.9%
- 10 Jun 2026+5.8%
Nothing announced by UNCY that day or the session before.
- 9 Jun 2026+9.2%
Nothing announced by UNCY that day or the session before.
- 26 May 2026-12.6%
Nothing announced by UNCY that day or the session before.
- 22 May 2026+5.9%
Nothing announced by UNCY that day or the session before.
Share of unusual movement by asset
For each asset, the share of UNCY's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Lanthanum-based intestinal phosphate binderSmall molecule | Chronic Kidney DiseaseHyperphosphatemia |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(8)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $2.8M | $44M+ $17M short-term inv. | $1.7M-$7.6M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | — | $1.6M | $37M+ $17M short-term inv. | $13M-$6.2M operating cash flow | report ↗ |
| 2025-Q3 | — | $3.0M | $43M | $6.0M-$6.0M operating cash flow | report ↗ |
| 2025-Q2 | — | $1.8M | $22M | $6.5M-$8.4M operating cash flow | report ↗ |
| 2025-Q1 | — | $2.2M | $20M | —-$8.9M operating cash flow | report ↗ |
| 2024-Q3 | — | $3.0M | $32M | $4.1M-$9.3M operating cash flow | report ↗ |
| 2024-Q2 | — | $4.9M | $42M | —-$6.3M operating cash flow | report ↗ |
| 2024-Q1 | — | $6.8M | $49M | $21M-$6.5M operating cash flow | report ↗ |
| 2023-Q3 | — | $3.4M | $14M | $4.3M-$4.4M operating cash flow | report ↗ |
| 2023-Q2 | — | $2.3M | $19M | $3.8M-$5.5M operating cash flow | report ↗ |
| 2023-Q1 | $0.7M | $3.0M | $24M | $15M-$3.9M operating cash flow | report ↗ |
| 2022-Q3 | $0.9M | $4.8M | $7.0M | $5.6M-$3.6M operating cash flow | report ↗ |
| 2022-Q2 | — | $1.9M | $11M | $3.6M-$3.0M operating cash flow | report ↗ |
| 2022-Q1 | — | $1.9M | $14M | $3.5M-$3.0M operating cash flow | report ↗ |
| 2021-Q3 | — | $3.8M | $18M | $5.2M-$3.5M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $9.1M | $29M+ $12M short-term inv. | $6.6M-$31M operating cash flow | report ↗ |
Unicycive Therapeutics reported no revenue for full-year 2025. R&D spend was $9.12M, down 54.4% YoY from $20.01M, while cash and equivalents were $29.2M at year-end and the company later reported $54.9M in cash, equivalents, and marketable securities as of March 30, 2026. Net loss attributable to common stockholders was $26.55M, or $1.67 per share, with quarterly net burn of $26.56M.
The FDA accepted the resubmitted New Drug Application for oxylanthanum carbonate (OLC) for hyperphosphatemia in dialysis patients, with a PDUFA target action date of June 29, 2026, and commercial readiness activities are ongoing toward a potential 3Q26 launch. The company expects its cash runway to extend into 2027, and it also highlighted its second candidate, UNI-494, for acute kidney injury-related conditions, which has completed a Phase 1 study and received orphan drug designation for prevention of delayed graft function.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-28 | Manning Meredith · director | Award / grant (derivative) | 3,350 | — | — | Form 4 |
| 2026-10-28 | Manning Meredith · director | Award / grant (derivative) | 27,000 | — | — | Form 4 |
| 2026-05-14 | Laumas Sandeep · director | Award / grant (derivative) | 47,941 | — | — | Form 4 |
| 2026-05-14 | Kenkare-Mitra Sara · director | Award / grant (derivative) | 47,941 | — | — | Form 4 |
| 2026-05-14 | Jermasek Douglas · EVP, Corporate Strategy | Award / grant (derivative) | 169,500 | — | — | Form 4 |
| 2026-05-14 | Townsend John · CFO | Award / grant (derivative) | 169,500 | — | — | Form 4 |
| 2026-05-14 | Gupta Pramod · EVP, Pharmaceuticals and BD | Award / grant (derivative) | 169,500 | — | — | Form 4 |
| 2026-05-14 | Laumas Sandeep · director | Award / grant (derivative) | 84,200 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 51 reporting institutions held 9.9M shares ($64.8M, 35.6% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Vivo Capital, LLC | 1,789,916 | $11.8M |
| 2 | MILLENNIUM MANAGEMENT LLC | 1,399,348 | $9.2M |
| 3 | Octagon Capital Advisors LP | 1,000,000 | $6.6M |
| 4 | Nantahala Capital Management, LLC | 939,202 | $6.2M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 811,430 | $5.3M |
| 6 | GREAT POINT PARTNERS LLC | 796,558 | $5.2M |
| 7 | Logos Global Management LP | 473,563 | $3.1M |
| 8 | CITADEL ADVISORS LLC | 236,841 | $1.6M |
| 9 | Integral Health Asset Management, LLC | 225,000 | $1.5M |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 203,744 | $1.3M |
| 11 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 199,219 | $1.3M |
| 12 | MORGAN STANLEY | 188,182 | $1.2M |
| 13 | MARSHALL WACE, LLP | 154,938 | $1.0M |
| 14 | Dauntless Investment Group, LLC | 147,087 | $968K |
| 15 | DIMENSIONAL FUND ADVISORS LP | 143,052 | $940K |